The quantum trade is shifting from a broad future-computing bet to a test of revenue, catalysts, and cash durability. IONQ, RGTI, and QBTS now need to prove they can close the gap with better-funded work at GOOG and IBM.
Quantum stocks no longer get to trade as one undifferentiated promise. The recent reset has exposed a sharper question: which companies are producing measurable commercial progress, and which are still asking investors to finance the next milestone? That distinction matters because the pure plays remain loss-making while carrying sales multiples that assume years of successful execution. We think the right benchmark is not which startup has the most persuasive roadmap, but which business can survive the wait long enough for quantum computing to become commercially meaningful.
The market is already forcing that distinction. IONQ
are all down year to date, but the damage has not been uniform: IonQ is down 6.5%, Rigetti is down 23.6%, and D-Wave is down 27.6%. That dispersion is not yet proof that the market has identified a winner. It is better understood as an early rejection of momentum trading as a sufficient investment case. Once the narrative premium fades, revenue quality, funding needs, and the credibility of each catalyst become harder to avoid.
Valuation shows why the standard pure-play comparison is inadequate. IonQ trades at 66.20 times sales, while Rigetti trades at 450.82 times and D-Wave at 603.59 times. Those figures do not merely price in growth; they leave very little room for delays, weak bookings, or another round of capital consumption. The contrast with the companies doing quantum work inside established franchises is stark: Alphabet trades at 9.31 times sales and IBM at 3.18 times. Neither incumbent is a clean quantum proxy, but that is precisely why they are useful benchmarks. They show what investors are paying for operating businesses that can fund research without making quantum the entire equity story.
The revenue numbers make the valuation gap more complicated, not less. IonQ reported revenue growth of 201.9%, and D-Wave reported growth of 178.5%, while Rigetti’s revenue declined 34.3%. Fast growth can justify a premium when it is converting into improving economics and repeatable demand. Here, however, the pure plays remain unprofitable, with negative P/E ratios and deeply negative net margins across the group. Growth is therefore evidence of activity, not yet evidence that the commercial model is working. The market should reward signed demand and improving unit economics more than another ambitious hardware or performance milestone.
IonQ has the strongest near-term case for asking investors to wait. Its 2026 revenue guidance was raised to $260 million-$270 million, with second-quarter guidance of $65 million-$68 million. It also had $493.5 million of cash and cash equivalents at March 31, 2026, alongside substantial short- and long-term investments. But the same filing recorded $151.0 million of operating cash burn in the quarter and $391.9 million of investing cash use. That combination is both reassuring and cautionary: IonQ has resources, yet it is still spending heavily to turn a promising platform into a durable business. The catalyst is not simply a higher guide; it is whether that guide arrives with evidence of repeat customers, commercial scale, and a path toward lower cash intensity.
Rigetti’s burden is different. The company says it has generated revenue since 2018 but has not yet generated profits. That admission makes the current debate less about ranking one roadmap against another and more about establishing what would invalidate the investment case. A claim such as deploying the industry’s largest multi-chip quantum computer may matter technologically, but it does not automatically answer the commercial questions. Investors need to see whether the deployment creates revenue, expands customer commitments, or improves the economics of the system. Until then, Rigetti’s negative 34.3% revenue growth leaves its 450.82 times sales valuation especially dependent on future execution.
D-Wave offers the clearest example of why headline growth is not the same as proof. Its 2025 revenue rose 179% to $24.6 million, but the company also reported a $355.1 million net loss. Cash and marketable securities reached $588.4 million at the end of the first quarter of 2026, up 93% from the prior-year quarter, giving the company more time to pursue its strategy. That runway is valuable, but it also highlights the mismatch between a modest revenue base and a 603.59 times sales multiple. The question is not whether D-Wave can fund another year of development. It is whether each additional year produces commercial evidence strong enough to justify the valuation before the market demands more capital.
Yes, quantum bulls can fairly argue that profits are the wrong test for an industry this early. They can point to IonQ’s raised revenue guide, D-Wave’s rapid growth, and Rigetti’s hardware roadmap as signs that platform execution deserves a premium. They can also argue that comparing pure plays with GOOG and IBM understates the upside because the incumbents are diversified and quantum is only a small part of their businesses. But that counterargument confuses upside potential with investment durability. Alphabet’s 26.08 times P/E and 54.8% net margin, alongside IBM’s 19.66 times P/E and 15.5% net margin, mean those companies can wait for quantum without asking the technology to carry their valuations today.
IBM makes that capital advantage explicit. The company reported $14.7 billion of free cash flow in 2025 and plans to invest more than $10 billion in quantum computing over the next five years. It also cites milestones toward quantum advantage in 2026 and fault tolerance by 2029. Those targets can still slip, and IBM is not immune to execution risk. The difference is that a delay would not threaten the company’s ability to keep funding the work. Alphabet has the same structural advantage through its much larger, profitable platform business. For the pure plays, a delayed catalyst can affect not only sentiment but also the terms and timing of future financing.
The August 5-6 earnings window sharpened this test. With IonQ reporting on August 5 and Rigetti and D-Wave on August 6, investors had a concentrated chance to compare bookings, revenue conversion, cash use, and forward milestones rather than simply trade a sector narrative. That shift should continue. The next meaningful distinction will be between companies that can point to commercial commitments and those that must keep moving the goalposts to the next technical achievement. A roadmap is a catalyst only when it changes the financial trajectory.
We are not dismissing quantum computing; we are rejecting the idea that every quantum equity deserves the same narrative premium. IONQ has the clearest disclosed revenue catalyst and meaningful resources, but it still needs to show that growth can become less cash-intensive. RGTI needs commercial validation beyond hardware milestones, while QBTS must demonstrate that rapid growth can overcome its small revenue base and heavy losses.
What would change our mind is measurable proof: recurring customer demand, revenue that scales faster than spending, and catalysts that reduce—not merely postpone—the need for capital. Until those signals arrive, GOOG and IBM remain the more durable ways to own quantum optionality, while the pure plays remain high-expectation experiments whose valuations demand delivery.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
